Immuron Limited has announced a new research agreement funded by a U.S. Department of Defense subaward, in collaboration with the Naval Medical Research Command (NMRC) and the Walter Reed Army Institute of Research (WRAIR). The grant supports the development of two new oral therapeutics targeting Campylobacter and Shigella. This project involves multiple organizations, including Immuron, NMRC, and WRAIR, and aims to produce hyper-immune bovine colostrum products for pre-clinical evaluation, specifically designed for the U.S. military.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Immuron Limited published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9595885-en) on December 03, 2025, and is solely responsible for the information contained therein.